Biotechnology
Commented by Stefan Feulner on December 13th, 2022 | 10:43 CET
Rheinmetall, Aspermont, BioNTech - Strong momentum
With its many drastic events, the turbulent stock market year 2022 is drawing to a close. With the Ukraine war, the change in monetary policy by central banks and rampant inflation, the year was characterized by strong uncertainty and high volatility, and it is almost certain to continue in the coming year. Nevertheless, the favourites are emerging more and more clearly from various sectors that should outperform the broad market in the months ahead.
ReadCommented by Armin Schulz on December 12th, 2022 | 10:20 CET
BioNTech, va-Q-tec, Cardiol Therapeutics, Ambrx Biopharma - Biotech second-line stocks explode
For investors in biotech stocks, 2022 was often a year to forget. After the Corona hype, the market clouded over significantly, in part due to rising interest rates. December is the time of year when investors can make adjustments to their portfolio, thereby reducing their tax burden for the year ahead. This year is no exception, yet three stocks shot up last Friday. That is unusual during tax loss season. We look at the three high flyers and BioNTech, a big player in the biotech sector.
ReadCommented by Stefan Feulner on December 8th, 2022 | 09:25 CET
Core One Labs, BioNxt Solutions, Moderna - Takeover battle in a billion-dollar market
The sharp correction of recent months hit the capital-intensive biotech sector particularly hard. Shares, mainly from the second tier, have, in some cases, had to absorb losses of more than three-quarters of their market value and are trading far below their cash levels. These distortions naturally attract the big players to acquire novel developments at bargain prices.
ReadCommented by Nico Popp on December 8th, 2022 | 09:05 CET
Where the money is made: BioNTech, Novavax, Cardiol Therapeutics
While the first federal states in Germany are lifting the mask requirement on public transport, suppliers of vaccines and medicines are far from going back to normal. Even corona vaccines are in high demand. While there is a shortage of antipyretics and medication in this country, especially for children, innovative companies are already addressing the next challenges. We explain where investors can make money.
ReadCommented by André Will-Laudien on December 5th, 2022 | 12:43 CET
Attention biotech stocks: Bayer, BioNTech, Defence Therapeutics and Morphosys - These stocks look good!
After months of selling off, they are back: biotech stocks! A strong turn on the NASDAQ quickly flushed the beaten-up stocks back to the top of the hit lists. With COVID out of the spotlight, companies are returning to their long-term research lines. These have been heavily focused on cancer in recent years, and now there is even groundbreaking news on metastasis. BioNTech has thus already gained more than 40% since the October low. Morphosys, on the other hand, lost another 40% after an Alzheimer's study failed to deliver valuable results. It is worth taking another look at the sector.
ReadCommented by Nico Popp on November 30th, 2022 | 13:33 CET
Advances in the fight against cancer: Arcus Biosciences, Gilead Sciences, Defence Therapeutics, BioNTech
Research studies from 2020 show that 72% of Germans fear cancer. However, very few people want to admit to these fears. But precisely because the subject is a big taboo, it is worth looking at the latest achievements in research. Many companies worldwide have long been fighting the epidemic - and making astonishing progress. Just recently, a US biotech announced encouraging study results. Other companies have yet to launch promising studies. We provide an overview and outline opportunities from an investor's perspective.
ReadCommented by Fabian Lorenz on November 30th, 2022 | 13:31 CET
Biotech stocks in focus: Morphosys, Evotec, Bayer, BioNxt Solutions
Biotech stocks have struggled in 2022. In Germany, BioNTech has overtaken the previous heavyweights Morphosys and Evotec in record time. Morphosys shocked investors with data on its Alzheimer's hope. Analysts lowered their thumbs, and short-sellers discovered the stock for themselves. Evotec has been quiet this year. Analysts think the valuation is attractive, but meeting earnings guidance in the current year is not a given. BioNxt shares have jumped recently, and if the positive newsflow continues into 2023, a re-rating is possible. At Bayer, the pharmaceuticals division is also developing positively. Conclusion: investors should position themselves for the biotech year 2023.
ReadCommented by Fabian Lorenz on November 24th, 2022 | 12:40 CET
New year, rising prices? BASF, BioNTech and Manuka Resources - Shares in check
As the stock market year 2022 draws to a close, we look ahead to 2023. New year, rising prices? That is what many stock market players are hoping for. The chances are that we will see rising indices again with the end of interest rate hikes in the coming year. Today, we look at three companies likely to attract attention in 2023. At BioNTech, the research pipeline is full to bursting, and there are numerous study results to come. BASF is attractive due to its low valuation and high dividend yield. However, analysts warn of a write-off risk. Manuka Ressources convinces with a profitable core business, and an exciting project in the field of critical raw materials could lead to a revaluation.
ReadCommented by Stefan Feulner on November 22nd, 2022 | 13:42 CET
Favorable starting positions for Commerzbank, Desert Gold and BioNTech
The suspected downward pressure due to uncertainties in the economy and geopolitics has so far failed to materialize. Instead, the most important stock indices, such as DAX or Dow Jones, were able to leave their short-term downward trends and are sending signals for a further upward push. In addition to the stock market, the precious metals sector was also able to turn around. Here, in particular, entry opportunities beckon at a significantly reduced level with the chance of long-term, disproportionate price gains.
ReadCommented by Nico Popp on November 21st, 2022 | 12:11 CET
Biotech - Hotter than ever: Catalyst Pharmaceuticals, BioNxt Solutions, Bayer
Biotechs have been providing answers to humanity's most pressing questions for years. Innovative companies are applying advanced methods to make a medical difference. The example of BioNTech is just one success story among many. While companies in the pharmaceutical sector are finding it increasingly difficult to come up with real innovations, biotechs often put all their eggs in one basket - and win. We present two biotech hopefuls and take a look at Bayer.
Read